Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263628 | 0.81 | TSHR (0.52) | KMT2AMEN1TSHRALDH1A1MAPT | |
| SCHEMBL3376695 | 0.80 | KDM4E (0.51) | KMT2AMEN1TSHRALDH1A1MAPT | |
| SCHEMBL2147241 | 0.80 | KMT2A (0.50) | KMT2AMEN1TSHRALDH1A1MAPT | |
| SCHEMBL161443 | 0.80 | KMT2A (0.50) | KMT2AMEN1TSHRALDH1A1MAPT | |
| SCHEMBL1444103 | 0.79 | TSHR (0.42) | KMT2ATSHRALDH1A1MAPTLMNA | |
| SCHEMBL20268131 | 0.79 | KMT2A (0.46) | KMT2AMEN1TSHRALDH1A1MAPT | |
| SCHEMBL23824155 | 0.79 | KMT2A (0.49) | KMT2AMEN1TSHRALDH1A1MAPT | |
| SCHEMBL3356162 | 0.79 | KMT2A (0.49) | KMT2AMEN1TSHRALDH1A1MAPT | |
| SCHEMBL309808 | 0.79 | ALDH1A1 (0.54) | KMT2AMEN1TSHRALDH1A1MAPT | |
| SCHEMBL370881 | 0.79 | KMT2A (0.49) | KMT2AMEN1TSHRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107406-A1 | p53 HETEROBIFUNCTIONAL CONJUGATES AND USES THEREOF | Design Therapeutics, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-08-21 | — | — | US | disclosed |
| US-12325697-B2 | CBL-B modulators and uses thereof | NIMBUS CLIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250066369-A1 | BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NodThera Limited (GB) | 2025-02-27 | — | — | US | disclosed |
| CN-114341127-B | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-118974033-A | Bcl-xL inhibitors | 百济神州有限公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-4460505-A1 | BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES | Nodthera Limited (GB) | 2024-11-13 | — | — | EP | disclosed |
| CN-118922421-A | Bicyclic phthalazin-1 (2H) -one derivatives and related uses | 诺瑟拉有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20240182426-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2024-06-06 | — | — | US | disclosed |
| US-20110263610-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2011-10-27 | — | — | US | disclosed |
| WO-2010138575-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305118-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010111059-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
| EP-2038280-A2 | FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2007143523-A2 | FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
| EP-1648884-A2 | PYRAZOLYL-INDOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005005414-A2 | PYRAZOLYL-INDOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | KIF2C, KIF5B, KIF5C | KMT2A 1148/4885MEN1 4063/4885TSHR 2005/4885 |
| US-20250066369-A1 | BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES | IL1B, NLRP3, IL1A | KMT2A 3863/4885MEN1 1336/4885TSHR 4687/4885 |
| US-20240182426-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | KMT2A 65/4885MEN1 1218/4885TSHR 3035/4885 |
| US-20100305118-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | IGF1R, TK1, CDK2 | KMT2A 2972/4885MEN1 945/4885TSHR 625/4885 |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | KMT2A 1054/4885MEN1 3984/4885TSHR 3636/4885 |
| US-20110263610-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K2, IP6K3 | KMT2A 2991/4885MEN1 2678/4885TSHR 3960/4885 |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | KMT2A 2307/4885MEN1 2805/4885TSHR 3774/4885 |
| US-12325697-B2 | CBL-B modulators and uses thereof | CBLB, CBL, CBLC | KMT2A 1054/4885MEN1 3984/4885TSHR 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.